CMX-2043

CMX-2043 is a small molecule drug developed as an analog of alpha-lipoic acid (ALA) with enhanced cytoprotective and antioxidant properties. It acts primarily as a modulator of the proto-oncogene protein c-Akt pathway, promoting cell survival and reducing oxidative damage. The compound has demonstrated greater potency than ALA in activating insulin receptor kinase and Akt phosphorylation. Preclinical studies showed efficacy in reducing myocardial ischemia-reperfusion injury and arrhythmias in animal models. Clinically, CMX-2043 has been investigated for the prevention of peri-operative cardiac ischemia-reperfusion injury during elective percutaneous coronary intervention (PCI), treatment of traumatic brain injury (TBI), non-ST elevation myocardial infarction (Non STEMI), unstable angina, stable coronary artery disease, and contrast-induced acute kidney injury. Phase I trials established a favorable safety profile; however, Phase II trials did not meet primary efficacy endpoints for cardiac or renal protection post-cardiac catheterization[1][2][3][4][5][6][8].

Other names

(R)-Lip-L-glu-L-ala-OH